Drug Patents owned by Cti Biopharma Corp
1. List of Vonjo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8153632 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
Jan, 2029
(5 years from now) | |
| US8980873 | CTI BIOPHARMA CORP | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9573964 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
May, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 28, 2029 |
| New Chemical Entity Exclusivity (NCE) | Feb 28, 2027 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 2026-02-28
Market Authorisation Date: 28 February, 2022
Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib
Dosage: CAPSULE;ORAL
VONJO family patents
17
United States
6
Korea, Republic of
4
Singapore
4
Taiwan, Province of China
3
Denmark
3
Australia
3
Hong Kong
3
Portugal
3
Spain
3
Poland
3
China
3
Japan
3
Canada
3
European Union
2
South Africa
2
Slovenia
2
Argentina
2
Brazil
2
Cyprus
2
Malaysia
2
New Zealand
1
Israel
1
Austria
1
Mexico
1
Russia
1
Germany
1
Croatia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic